Merkel cell cancer natural history: Difference between revisions

Jump to navigation Jump to search
No edit summary
 
(8 intermediate revisions by one other user not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Merkel cell cancer}}
{{Merkel cell cancer}}
{{CMG}} {{AE}} {{AAM}}
{{CMG}} ; {{AE}} {{VKG}} {{AAM}}
==Overview==
==Overview==
Merkel cell cancer is an aggressive skin tumor that grows rapidly. It usually metastasizes first to regional lymph nodes and then to other distant organs. and spreads to other parts of the body, especially the liver, lungs, brain and bones. Merkel cell carcinoma is a highly aggressive tumor with a mortality rate that approaches 30% to 40% within 3 years of diagnosis. If diagnosed early, Merkel cell cancer has a good prognosis with a 5-year survival rate of approximately 90%.  
Merkel cell cancer is an aggressive [[cutaneous]] cancer that grows very rapidly. Merkel cell cancer usually [[Metastasis|metastasizes]] first to regional [[Lymph node|lymph nodes]]. Merkel cell cancer is a highly aggressive [[tumor]] with a [[mortality]] rate that approaches 30% to 40% within 3 years of diagnosis.  


== Natural History, Complications, and Prognosis ==
== Natural History, Complications, and Prognosis ==


===Natural History===
===Natural History===
*Merkel cell cancer is an aggressive skin tumor that grows rapidly.
*Merkel cell cancer is an aggressive [[cutaneous]] [[tumor]] that grows rapidly.
*It usually metastasizes first to regional lymph nodes and then to other distant organs. and spreads to other parts of the body, especially the liver, lungs, brain and bones.
*[[Merkel cell cancer]] usually [[Metastasize|metastasizes]] to
**[[Lymph nodes]]
**[[Liver]]
**[[Lungs]]
**[[Brain]] 
**[[Bones]]
===Complications===
===Complications===
Common complications of [disease name] include:
Common [[complications]] of [[merkel cell carcinoma]] include:<ref name="pmid112432822">{{cite journal |vauthors=Eggers SD, Salomao DR, Dinapoli RP, Vernino S |title=Paraneoplastic and metastatic neurologic complications of Merkel cell carcinoma |journal=Mayo Clin. Proc. |volume=76 |issue=3 |pages=327–30 |date=March 2001 |pmid=11243282 |doi=10.4065/76.3.327 |url=}}</ref>
* [Complication 1]
* [[Neurology|Neurologic]] [[complications]] which include:<ref name="pmid7760100">{{cite journal |vauthors=Snodgrass SM, Landy H, Markoe AM, Feun L |title=Neurologic complications of Merkel cell carcinoma |journal=J. Neurooncol. |volume=22 |issue=3 |pages=231–4 |date=1994 |pmid=7760100 |doi= |url=}}</ref>
* [Complication 2]
** [[Seizure|Seizures]]
* [Complication 3]
** Bilateral radiculopathies
** [[Myoclonus]]
** [[Cauda equina syndrome]]
** Altered mental status
* [[Leptomeningeal]] [[carcinomatosis]]


===Prognosis===
===Prognosis===
*Merkel cell carcinoma is a highly aggressive tumor with a mortality rate that approaches 30% to 40% within 3 years of diagnosis.  
*Merkel cell cancer is a highly aggressive tumor with a [[mortality]] rate that approaches 30% to 40% within 3 years of diagnosis.  
*If diagnosed early, merkel cell cancer has a good prognosis with a 5-year survival rate of approximately 90%.
*If diagnosed early, merkel cell carcinoma has a good prognosis with a 5-year survival rate of approximately 90%.
*The prognosis depend on the following:<ref name="pmid18798233">{{cite journal |vauthors=Andea AA, Coit DG, Amin B, Busam KJ |title=Merkel cell carcinoma: histologic features and prognosis |journal=Cancer |volume=113 |issue=9 |pages=2549–58 |date=November 2008 |pmid=18798233 |doi=10.1002/cncr.23874 |url=}}</ref><ref name="pmid21422430">{{cite journal |vauthors=Paulson KG, Iyer JG, Tegeder AR, Thibodeau R, Schelter J, Koba S, Schrama D, Simonson WT, Lemos BD, Byrd DR, Koelle DM, Galloway DA, Leonard JH, Madeleine MM, Argenyi ZB, Disis ML, Becker JC, Cleary MA, Nghiem P |title=Transcriptome-wide studies of merkel cell carcinoma and validation of intratumoral CD8+ lymphocyte invasion as an independent predictor of survival |journal=J. Clin. Oncol. |volume=29 |issue=12 |pages=1539–46 |date=April 2011 |pmid=21422430 |pmc=3082974 |doi=10.1200/JCO.2010.30.6308 |url=}}</ref><ref name="pmid22467679">{{cite journal |vauthors=Sihto H, Böhling T, Kavola H, Koljonen V, Salmi M, Jalkanen S, Joensuu H |title=Tumor infiltrating immune cells and outcome of Merkel cell carcinoma: a population-based study |journal=Clin. Cancer Res. |volume=18 |issue=10 |pages=2872–81 |date=May 2012 |pmid=22467679 |doi=10.1158/1078-0432.CCR-11-3020 |url=}}</ref>
*The prognosis depend on the following:<ref name="pmid18798233">{{cite journal |vauthors=Andea AA, Coit DG, Amin B, Busam KJ |title=Merkel cell carcinoma: histologic features and prognosis |journal=Cancer |volume=113 |issue=9 |pages=2549–58 |date=November 2008 |pmid=18798233 |doi=10.1002/cncr.23874 |url=}}</ref><ref name="pmid21422430">{{cite journal |vauthors=Paulson KG, Iyer JG, Tegeder AR, Thibodeau R, Schelter J, Koba S, Schrama D, Simonson WT, Lemos BD, Byrd DR, Koelle DM, Galloway DA, Leonard JH, Madeleine MM, Argenyi ZB, Disis ML, Becker JC, Cleary MA, Nghiem P |title=Transcriptome-wide studies of merkel cell carcinoma and validation of intratumoral CD8+ lymphocyte invasion as an independent predictor of survival |journal=J. Clin. Oncol. |volume=29 |issue=12 |pages=1539–46 |date=April 2011 |pmid=21422430 |pmc=3082974 |doi=10.1200/JCO.2010.30.6308 |url=}}</ref><ref name="pmid22467679">{{cite journal |vauthors=Sihto H, Böhling T, Kavola H, Koljonen V, Salmi M, Jalkanen S, Joensuu H |title=Tumor infiltrating immune cells and outcome of Merkel cell carcinoma: a population-based study |journal=Clin. Cancer Res. |volume=18 |issue=10 |pages=2872–81 |date=May 2012 |pmid=22467679 |doi=10.1158/1078-0432.CCR-11-3020 |url=}}</ref><ref name="pmid25239411">{{cite journal |vauthors=Paulson KG, Iyer JG, Simonson WT, Blom A, Thibodeau RM, Schmidt M, Pietromonaco S, Sokil M, Warton EM, Asgari MM, Nghiem P |title=CD8+ lymphocyte intratumoral infiltration as a stage-independent predictor of Merkel cell carcinoma survival: a population-based study |journal=Am. J. Clin. Pathol. |volume=142 |issue=4 |pages=452–8 |date=October 2014 |pmid=25239411 |pmc=4174450 |doi=10.1309/AJCPIKDZM39CRPNC |url=}}</ref>
**Stage at diagnosis (1st most potent prognostic factor)
**Stage at diagnosis (1st most potent [[prognostic]] factor).
**Lymph Node involvement (2nd most important prognostic factor)
**[[Lymph node]] involvement (2nd most important [[prognostic]] factor).
**Merkel cell polyomavirus (MCPyV) viral load also play an significant role in prognosis of merkel cell cancer
**[[Merkel cell]] [[polyomavirus]] (MCPyV) viral load also play an significant role in prognosis of merkel cell cancer.
**Cancer location
**[[Cancer]] location
**Cancer depth
**[[Cancer]] depth
**Primary vs recurrent
**Primary vs recurrent
*'''Lymphovascular invasion''' in merkel cell cancer patients associated with poor prognosis
*'''Lymphovascular [[invasion]]''' in merkel cell cancer patients associated with poor prognosis.
*'''Intratumoral lymphocyte infiltration''' in merkel cell cancer patients associated with good prognosis due to presence of CD8+ lymphocyte infiltration<ref name="pmid21865945">{{cite journal |vauthors=Fields RC, Busam KJ, Chou JF, Panageas KS, Pulitzer MP, Allen PJ, Kraus DH, Brady MS, Coit DG |title=Five hundred patients with Merkel cell carcinoma evaluated at a single institution |journal=Ann. Surg. |volume=254 |issue=3 |pages=465–73; discussion 473–5 |date=September 2011 |pmid=21865945 |doi=10.1097/SLA.0b013e31822c5fc1 |url=}}</ref>
*'''Intratumoral [[lymphocyte]] infiltration''' in merkel cell cancer patients associated with good prognosis due to presence of [[CD8]]+ [[lymphocyte]] [[Infiltration (medical)|infiltration]].<ref name="pmid21865945">{{cite journal |vauthors=Fields RC, Busam KJ, Chou JF, Panageas KS, Pulitzer MP, Allen PJ, Kraus DH, Brady MS, Coit DG |title=Five hundred patients with Merkel cell carcinoma evaluated at a single institution |journal=Ann. Surg. |volume=254 |issue=3 |pages=465–73; discussion 473–5 |date=September 2011 |pmid=21865945 |doi=10.1097/SLA.0b013e31822c5fc1 |url=}}</ref>
*'''p63 expression''' in merkel cell cancer patients associated with poor prognosis
*'''p63 expression''' in [[merkel cell cancer]] patients associated with poor [[prognosis]].
==References==
==References==
{{Reflist|2}}
{{Reflist|2}}

Latest revision as of 02:34, 31 January 2019

Merkel cell cancer Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Merkel Cell Cancer from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Staging

History and Symptoms

Physical Examination

Laboratory Findings

CT

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Merkel cell cancer natural history On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Merkel cell cancer natural history

All Images
X-rays
Echo and Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Merkel cell cancer natural history

CDC on Merkel cell cancer natural history

Merkel cell cancer natural history in the news

Blogs on Merkel cell cancer natural history

Directions to Hospitals Treating Merkel cell cancer

Risk calculators and risk factors for Merkel cell cancer natural history

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: Vamsikrishna Gunnam M.B.B.S [2] Ahmad Al Maradni, M.D. [3]

Overview

Merkel cell cancer is an aggressive cutaneous cancer that grows very rapidly. Merkel cell cancer usually metastasizes first to regional lymph nodes. Merkel cell cancer is a highly aggressive tumor with a mortality rate that approaches 30% to 40% within 3 years of diagnosis.

Natural History, Complications, and Prognosis

Natural History

Complications

Common complications of merkel cell carcinoma include:[1]

Prognosis

  • Merkel cell cancer is a highly aggressive tumor with a mortality rate that approaches 30% to 40% within 3 years of diagnosis.
  • If diagnosed early, merkel cell carcinoma has a good prognosis with a 5-year survival rate of approximately 90%.
  • The prognosis depend on the following:[3][4][5][6]
  • Lymphovascular invasion in merkel cell cancer patients associated with poor prognosis.
  • Intratumoral lymphocyte infiltration in merkel cell cancer patients associated with good prognosis due to presence of CD8+ lymphocyte infiltration.[7]
  • p63 expression in merkel cell cancer patients associated with poor prognosis.

References

  1. Eggers SD, Salomao DR, Dinapoli RP, Vernino S (March 2001). "Paraneoplastic and metastatic neurologic complications of Merkel cell carcinoma". Mayo Clin. Proc. 76 (3): 327–30. doi:10.4065/76.3.327. PMID 11243282.
  2. Snodgrass SM, Landy H, Markoe AM, Feun L (1994). "Neurologic complications of Merkel cell carcinoma". J. Neurooncol. 22 (3): 231–4. PMID 7760100.
  3. Andea AA, Coit DG, Amin B, Busam KJ (November 2008). "Merkel cell carcinoma: histologic features and prognosis". Cancer. 113 (9): 2549–58. doi:10.1002/cncr.23874. PMID 18798233.
  4. Paulson KG, Iyer JG, Tegeder AR, Thibodeau R, Schelter J, Koba S, Schrama D, Simonson WT, Lemos BD, Byrd DR, Koelle DM, Galloway DA, Leonard JH, Madeleine MM, Argenyi ZB, Disis ML, Becker JC, Cleary MA, Nghiem P (April 2011). "Transcriptome-wide studies of merkel cell carcinoma and validation of intratumoral CD8+ lymphocyte invasion as an independent predictor of survival". J. Clin. Oncol. 29 (12): 1539–46. doi:10.1200/JCO.2010.30.6308. PMC 3082974. PMID 21422430.
  5. Sihto H, Böhling T, Kavola H, Koljonen V, Salmi M, Jalkanen S, Joensuu H (May 2012). "Tumor infiltrating immune cells and outcome of Merkel cell carcinoma: a population-based study". Clin. Cancer Res. 18 (10): 2872–81. doi:10.1158/1078-0432.CCR-11-3020. PMID 22467679.
  6. Paulson KG, Iyer JG, Simonson WT, Blom A, Thibodeau RM, Schmidt M, Pietromonaco S, Sokil M, Warton EM, Asgari MM, Nghiem P (October 2014). "CD8+ lymphocyte intratumoral infiltration as a stage-independent predictor of Merkel cell carcinoma survival: a population-based study". Am. J. Clin. Pathol. 142 (4): 452–8. doi:10.1309/AJCPIKDZM39CRPNC. PMC 4174450. PMID 25239411.
  7. Fields RC, Busam KJ, Chou JF, Panageas KS, Pulitzer MP, Allen PJ, Kraus DH, Brady MS, Coit DG (September 2011). "Five hundred patients with Merkel cell carcinoma evaluated at a single institution". Ann. Surg. 254 (3): 465–73, discussion 473–5. doi:10.1097/SLA.0b013e31822c5fc1. PMID 21865945.